What is the stock price prediction for Editas in 2025? (2024)

What is the stock price prediction for Editas in 2025?

EDIT Stock 12 Month Forecast

Based on 11 Wall Street analysts offering 12 month price targets for Editas Medicine in the last 3 months. The average price target is $14.33 with a high forecast of $27.00 and a low forecast of $9.00. The average price target represents a 158.20% change from the last price of $5.55.

What is the future of Editas stock?

EDIT Stock 12 Month Forecast

Based on 11 Wall Street analysts offering 12 month price targets for Editas Medicine in the last 3 months. The average price target is $14.33 with a high forecast of $27.00 and a low forecast of $9.00. The average price target represents a 158.20% change from the last price of $5.55.

Is Editas a good investment?

Editas Medicine, Inc.

may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of EDIT, demonstrate its potential to underperform the market. It currently has a Growth Score of C.

What is the CRISPR stock forecast for 2030?

CRISPR Therapeutics AG stock prediction for 1 year from now: $ 82.22 (46.48%) CRISPR Therapeutics AG stock forecast for 2025: $ 75.22 (34.02%) CRISPR Therapeutics AG stock prediction for 2030: $ 325.19 (479.35%)

What is the open stock forecast for 2025?

Opendoor Technologies Inc. stock forecast for 2025: $ 3.35 (49.92%) Opendoor Technologies Inc. stock prediction for 2030: $ 25.38 (1,035.51%)

Will Editas stock go up?

Editas expects to report a significant amount of data from the SCD trial sometime in the middle of 2024. If that data confirms the prior positive findings, expect the stock to rise promptly.

Is Editas a good company?

Editas Medicine has an overall rating of 3.6 out of 5, based on over 48 reviews left anonymously by employees. 57% of employees would recommend working at Editas Medicine to a friend and 57% have a positive outlook for the business. This rating has decreased by -1% over the last 12 months.

Why is Editas stock falling?

Over the last three years, Editas Medicine's revenue dropped 60% per year. That means its revenue trend is very weak compared to other loss making companies. The swift share price decline at an annual compound rate of 23%, reflects this weak fundamental performance.

Is Editas overvalued?

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. Flawless balance sheet and slightly overvalued.

Who invested in Editas?

Largest shareholders include Vanguard Group Inc, BlackRock Inc., Deep Track Capital, LP, State Street Corp, XBI - SPDR(R) S&P(R) Biotech ETF, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Dimensional Fund Advisors Lp, IWM - iShares Russell 2000 ETF, NAESX - Vanguard Small-Cap Index Fund Investor ...

What CRISPR company did Bill Gates invest in?

Our genius IT CEO Bill Gates and his friends decided to put their hands to “The Genesis Engine”, the new favorite of DNA editing in the lab, CRISPR. They poured $120 Million, as the title of this article said, into this project for a company named Editas Medicine, which lead the CRISPR to the world.

Where will CRISPR be in 10 years?

Over the next 10 years, we expect the biomedical applications of CRISPR to accelerate: A second wave of in vivo clinical trials including larger indications.

What is the best CRISPR stock to buy?

What is III stock forecast for 2025?

The Wall Street analyst predicted that Information Services Group's share price could reach $5.00 by Mar 11, 2025. The average Information Services Group stock price prediction forecasts a potential upside of 28.53% from the current III share price of $3.89.

What is the target stock price forecast for 2024?

Target Stock Price Forecast 2024-2025

Target price started in 2024 at $134.78. Today, Target traded at $177.21, so the price increased by 31% from the beginning of the year. The forecasted Target price at the end of 2024 is $236 - and the year to year change +75%.

What will SoFi stock price be in 2025?

SoFi Technologies, Inc. stock prediction for 1 year from now: $ 16.17 (124.52%) SoFi Technologies, Inc. stock forecast for 2025: $ 8.34 (14.07%)

Does Editas own CRISPR?

After that decision, Editas became the exclusive licensee of certain CRISPR patents for developing human medicines, including a Cas9 patent estate owned and co-owned by Harvard University, Broad Institute, the Massachusetts Institute of Technology and Rockefeller University.

What are the analyst ratings for Editas stock?

How many people work at Editas?

What is Editas working on?

Editas Medicine is developing CRISPR medicines for 2 major blood diseases: SCD and beta-thalassemia.

Where is Editas based?

Our corporate headquarters is located in Cambridge, MA, and we have a significant and growing site in Boulder, CO. We are pioneering the possibilities of genomic medicines through gene editing.

Is CRISPR a buy hold or sell?

Is CRSP a Buy, Sell or Hold? Crispr Therapeutics AG has a conensus rating of Moderate Buy which is based on 10 buy ratings, 5 hold ratings and 2 sell ratings.

Why is Edit stock up?

The massive uptick in revenues was primarily driven by payments received under Editas' licensing agreement with Vertex VRTX during the fourth quarter. In December 2023, Vertex in-licensed rights to Editas' Cas9 gene editing tool to develop its newly approved sickle cell disease (SCD) gene therapy, Casgevy.

Is CRISPR a good company to invest in?

CRISPR Therapeutics received important regulatory approvals last year. The company could make plenty of money on its lone marketed product. There should be more regulatory breakthroughs for the biotech ahead.

Is Editas medicine profitable?

Editas Medicine isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Shareholders of unprofitable companies usually desire strong revenue growth.